- Home
- NDRA vs APRE Comparison
NDRA vs APRE Comparison
Compare NDRA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- APRE
- Stock Information
- Founded
- NDRA 2007
- APRE 2006
- Country
- NDRA United States
- APRE United States
- Employees
- NDRA N/A
- APRE N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDRA Health Care
- APRE Health Care
- Exchange
- NDRA Nasdaq
- APRE Nasdaq
- Market Cap
- NDRA 7.3M
- APRE 6.9M
- IPO Year
- NDRA 2017
- APRE 2019
- Fundamental
- Price
- NDRA $4.53
- APRE $1.16
- Analyst Decision
- NDRA Strong Buy
- APRE Strong Buy
- Analyst Count
- NDRA 1
- APRE 1
- Target Price
- NDRA $38.00
- APRE $20.00
- AVG Volume (30 Days)
- NDRA 45.9K
- APRE 84.3K
- Earning Date
- NDRA 11-17-2025
- APRE 11-12-2025
- Dividend Yield
- NDRA N/A
- APRE N/A
- EPS Growth
- NDRA N/A
- APRE N/A
- EPS
- NDRA N/A
- APRE N/A
- Revenue
- NDRA N/A
- APRE $488,239.00
- Revenue This Year
- NDRA N/A
- APRE N/A
- Revenue Next Year
- NDRA N/A
- APRE N/A
- P/E Ratio
- NDRA N/A
- APRE N/A
- Revenue Growth
- NDRA N/A
- APRE N/A
- 52 Week Low
- NDRA $2.90
- APRE $1.08
- 52 Week High
- NDRA $11.96
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- NDRA 42.26
- APRE 37.51
- Support Level
- NDRA $6.06
- APRE $1.08
- Resistance Level
- NDRA $6.80
- APRE $1.28
- Average True Range (ATR)
- NDRA 0.84
- APRE 0.09
- MACD
- NDRA -0.12
- APRE -0.01
- Stochastic Oscillator
- NDRA 23.44
- APRE 30.53
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.